Huashan Hospital
Shanghai, Shanghai Municipality, 200000, China
Location status: Recruiting
NCT Number: NCT04025944
This study is aimed to collect and analyze clinical data of patients with chronic viral hepatitis in the real world, to investigate the long-term outcome of these patients and to optimize treatment options based on these data.
Interested in participating?
Request Info18 year–75 year
All sexes
Observational
Shanghai, Shanghai Municipality, 200000, China
Location status: Recruiting
Chronic viral hepatitis is defined as infectious liver disease caused by persistent virus infection for more than six months. Sustained viral replication and ongoing liver inflammation can eventually lead to liver fibrosis/cirrhosis or even hepatocellular carcinoma. Chronic viral hepatitis infection causes at least 80% of all liver cancers.
Though chronic viral hepatitis is a major global health concern, there is still a lack of evidence in high quality about the management of chronic viral hepatitis and the long-term outcome of patients. The concept of real-world data and research has been officially introduced into China since 2010. Real-world evidence, based on real-world data, can help practitioners have better understanding of the characteristics of the patients with different treatment strategies.
This study is aimed to collect and analyze clinical data of patients with chronic viral hepatitis in the real world, to investigate the long-term outcome of these patients and to optimize treatment options based on these data.
Only the study team can determine whether someone qualifies for participation.
Inclusion criteria
Exclusion criteria
Time frame: 24 weeks after treatment initiation
Sustained virological response (Able to sustain an undetectable viral load for a period)
Time frame: 48 weeks after treatment initiation
Hepatitis B e antigen (HBeAg) seroconversion(HBeAg loss and presence of anti-HBe) and hepatitis B surface antigen(HBsAg) seroconversion (HBsAg loss and presence of anti-HBs)
Time frame: 48 weeks after treatment initiation
Significant improvement in fibrosis was defined as a decrease in the Ishak score of at least 1 point; (the Ishak score describes six stages of fibrosis, 0 for No fibrosis and 6 for Cirrhosis; higher the Ishak score is, more severe the fibrosis is).
Contact information is provided by the study sponsor or research team.
Huashan Hospital
Other
OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.
View the official ClinicalTrials.gov record (opens in a new tab)This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.
Published trials that share one or more normalized conditions with this study.
NCT00287235
Brain Diseases, Brain Diseases, Metabolic
Birmingham, Alabama, United States
View Trial DetailsNCT02662712
Chronic Disease, Digestive System Diseases
Brussels, Belgium
View Trial DetailsNCT00913757
Adenocarcinoma, Alcohol-Induced Disorders
Baltimore, Maryland, United States
View Trial DetailsNCT01980290
Chronic Disease, Digestive System Diseases
Antwerp, Belgium
View Trial Details